Zydus hits 52-week high, can the optimism continue?
A quarterly results development with market-wide reach.
29 Sept 2026 · LiveMint Markets
Zydus Lifesciences has gained 32% in 2026, helped by favourable US FDA inspections, resilient India growth and a strong pipeline, but US weakness and margin pressure remain key risks.
The analysis
This is an USFDA action event. US regulatory status gates the export revenue that drives most Indian pharma earnings. A clearance reopens filings from that site; an alert freezes them, and the impact lands over quarters rather than days.
Related coverage
Invesco and Motilal Oswal lead AUM growth in Q2 FY27, shows data
TCS Q2 earnings: Five things to watch as Tata boardroom fight adds to scrutiny
Q2 Results Preview: Nifty 50 Earnings May Jump 27%; Financials, Metals, Telecom To Lead, Says Motilal Oswal
Penny stock under ₹10 hits 5% upper circuit after this fundraising update | Do you own?
Trent’s Rs 1.80 lakh crore rout from peak: Has Q2 just flipped the script for Tata group’s retail crown jewel?